Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells

Journal of Cellular Biochemistry

Volumn 115, Issue 10, 2014, Pages 1799-1807

  Lu, Wenyan ^a   Li, Yonghe ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

CANCER; LRP6; mTORC1 SIGNALING; SALINOMYCIN; Wnt SIGNALING

Indexed keywords

BETA CATENIN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; SALINOMYCIN; SURVIVIN; WNT PROTEIN; ANTIINFECTIVE AGENT; BIRC5 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INHIBITOR OF APOPTOSIS PROTEIN; LRP6 PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PYRAN DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; EMBRYO; ENZYME ACTIVATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MCF 7 CELL LINE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; FEMALE; MALE; METABOLISM; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ANTI-BACTERIAL AGENTS; APOPTOSIS; BETA CATENIN; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; ENZYME ACTIVATION; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; MALE; MCF-7 CELLS; MULTIPROTEIN COMPLEXES; PROSTATE; PROSTATIC NEOPLASMS; PYRANS; TOR SERINE-THREONINE KINASES; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84906097398     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24850     Document Type: Article

References (49)

1. Anastas JN, Moon RT,. 2013. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13: 11-26.
2. Averous J, Fonseca BD, Proud CG,. 2008. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 27: 1106-1113.
3. Castilho RM, Squarize CH, Chodosh LA, Williams BO, Gutkind JS,. 2009. MTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell 5: 279-289.
4. Clevers H, Nusse R,. 2012. Wnt/beta-catenin signaling and disease. Cell 149: 1192-1205.
5. Dancey J,. 2010. MTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7: 209-219.
6. Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD, Schuller AG, Yuan J, Ospina B, Green J, Yu Q, Walsh R, Li S, Schmitz R, Heine H, Bilic S, Ostrom L, Mosher R, Hartlepp KF, Zhu Z, Fawell S, Yao YM, Stover D, Finan PM, Porter JA, Sellers WR, Klagge IM, Cong F,. 2010. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci USA 107: 15473-15478.
7. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM,. 2008. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci USA 105: 13544-13549.
8. Gao C, Cao W, Bao L, Zuo W, Xie G, Cai T, Fu W, Zhang J, Wu W, Zhang X, Chen YG,. 2010. Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation. Nat Cell Biol 12: 781-790.
9. Garcia JA, Danielpour D,. 2008. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 7: 1347-1354.
10. Gong Y, Bourhis E, Chiu C, Stawicki S, DeAlmeida VI, Liu BY, Phamluong K, Cao TC, Carano RA, Ernst JA, Solloway M, Rubinfeld B, Hannoush RN, Wu Y, Polakis P, Costa M,. 2010. Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS One 5: e12682.
11. Guertin DA, Sabatini DM,. 2007. Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
12. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES,. 2009. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659.
13. Hagenmueller M, Malekar P, Fieger C, Weiss CS, Buss SJ, Wolf D, Katus HA, Hardt SE,. 2010. Depletion of mammalian target of rapamycin (mTOR) via siRNA mediated knockdown leads to stabilization of beta-catenin and elicits distinct features of cardiomyocyte hypertrophy. FEBS Lett 584: 74-80.
14. Hao HX, Xie Y, Zhang Y, Charlat O, Oster E, Avello M, Lei H, Mickanin C, Liu D, Ruffner H, Mao X, Ma Q, Zamponi R, Bouwmeester T, Finan PM, Kirschner MW, Porter JA, Serluca FC, Cong F,. 2012. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 485: 195-200.
15. Huang J, Nguyen-McCarty M, Hexner EO, Danet-Desnoyers G, Klein PS,. 2012. Maintenance of hematopoietic stem cells through regulation of Wnt and mTOR pathways. Nat Med 18: 1778-1785.
16. Huang J, Zhang Y, Bersenev A, O'Brien WT, Tong W, Emerson SG, Klein PS,. 2009. Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. J Clin Invest 119: 3519-3529.
17. Huczynski A,. 2012. Salinomycin: A new cancer drug candidate. Chem Biol Drug Des 79: 235-238.
18. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL,. 2006. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955-968.
19. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC,. 2003. Survivin and molecular pathogenesis of colorectal cancer. Lancet 362: 205-209.
20. King TD, Suto MJ, Li Y,. 2012. The Wnt/beta-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem 113: 13-18.
21. Koo BK, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, van Es JH, Mohammed S, Heck AJ, Maurice MM, Clevers H,. 2012. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488: 665-669.
22. Kwan HT, Chan DW, Cai PC, Mak CS, Yung MM, Leung TH, Wong OG, Cheung AN, Ngan HY,. 2013. AMPK activators suppress cervical cancer cell growth through inhibition of DVL3 mediated Wnt/beta-catenin signaling activity. PLoS One 8: e53597.
23. Li Y, Lu W, He X, Schwartz AL, Bu G,. 2004. LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering beta-catenin subcellular distribution. Oncogene 23: 9129-9135.
24. Lin C, Lu W, Zhai L, Bethea T, Berry K, Qu Z, Waud WR, Li Y,. 2011. Mesd is a general inhibitor of different Wnt ligands in Wnt/LRP signaling and inhibits PC-3 tumor growth in vivo. FEBS Lett 585: 3120-3125.
25. Lin C, Lu W, Zhang W, Londono-Joshi AI, Buchsbaum DJ, Bu G, Li Y,. 2013. The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/beta-catenin signaling in cancer cells. PLoS One 8: e58102.
26. Lindvall C, Zylstra CR, Evans N, West RA, Dykema K, Furge KA, Williams BO,. 2009. The Wnt co-receptor Lrp6 is required for normal mouse mammary gland development. PLoS One 4: e5813.
27. Liu CC, Prior J, Piwnica-Worms D, Bu G,. 2010. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci USA 107: 5136-5141.
28. Liu W, Singh R, Choi CS, Lee HY, Keramati AR, Samuel VT, Lifton RP, Shulman GI, Mani A,. 2012a. Low density lipoprotein (LDL) receptor-related protein 6 (LRP6) regulates body fat and glucose homeostasis by modulating nutrient sensing pathways and mitochondrial energy expenditure. J Biol Chem 287: 7213-7223.
29. Liu W, Xing F, Iiizumi-Gairani M, Okuda H, Watabe M, Pai SK, Pandey PR, Hirota S, Kobayashi A, Mo YY, Fukuda K, Li Y, Watabe K,. 2012b. N-myc downstream regulated gene 1 modulates Wnt-beta-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med 4: 93-108.
30. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA,. 2011a. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA 108: 13253-13257.
31. Lu W, Kim KA, Liu J, Abo A, Feng X, Cao X, Li Y,. 2008. R-spondin1 synergizes with Wnt3A in inducing osteoblast differentiation and osteoprotegerin expression. FEBS Lett 582: 643-650.
32. Lu W, Lin C, King TD, Chen H, Reynolds RC, Li Y,. 2012. Silibinin inhibits Wnt/beta-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. Cell Signal 24: 2291-2296.
33. Lu W, Lin C, Li Y,. 2014. Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/beta-catenin and mTORC1 signaling in prostate and breast cancer cells. Cell Signal 26: 1303-1309.
34. Lu W, Lin C, Roberts MJ, Waud WR, Piazza GA, Li Y,. 2011b. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway. PLoS One 6: e29290.
35. Lu W, Liu CC, Thottassery JV, Bu G, Li Y,. 2010. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells. Biochemistry 49: 4635-4643.
36. Ma H, Nguyen C, Lee KS, Kahn M,. 2005. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 24: 3619-3631.
37. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, Glinka A, Niehrs C,. 2002. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417: 664-667.
38. Miyazaki Y, Shibuya M, Sugawara H, Kawaguchi O, Hirsoe C,. 1974. Salinomycin, a new polyether antibiotic. J Antibiot (Tokyo) 27: 814-821.
39. Naujokat C, Steinhart R,. 2012. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol 2012: 950658.
40. Park DS, Seo JH, Hong M, Choi SC,. 2013. Role of the Rap2/TNIK kinase pathway in regulation of LRP6 stability for Wnt signaling. Biochem Biophys Res Commun 436: 338-343.
41. Polakis P,. 2012. Drugging Wnt signalling in cancer. EMBO J 31: 2737-2746.
42. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A,. 1999. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96: 5522-5527.
43. Tahir SA, Yang G, Goltsov A, Song KD, Ren C, Wang J, Chang W, Thompson TC,. 2013. Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer. Cancer Res 73: 1900.
44. Tetsu O, McCormick F,. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426.
45. Tung EK, Wong BY, Yau TO, Ng IO,. 2012. Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion. PLoS One 7: e36565.
46. Vaira V, Lee CW, Goel HL, Bosari S, Languino LR, Altieri DC,. 2007. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 26: 2678-2684.
47. Valvezan AJ, Huang J, Lengner CJ, Pack M, Klein PS,. 2014. Oncogenic mutations in adenomatous polyposis coli (Apc) activate mechanistic target of rapamycin complex 1 (mTORC1) in mice and zebrafish. Dis Model Mech 7: 63-71.
48. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, Deng X, Chen L, Kim CC, Lau S, Somlo G, Yen Y,. 2011. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 30: 4437-4446.
49. Zhou S, Wang F, Wong ET, Fonkem E, Hsieh TC, Wu JM, Wu E,. 2013. Salinomycin: a novel anti-cancer agent with known anti-coccidial activities. Curr Med Chem 20: 4095-4101.